A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia
Hocepied, A.M.; Falkson, C.I.; Falkson, G.
South African Medical Journal 86(5): 549-550
1996
ISSN/ISBN: 0256-9574 PMID: 8711555 Document Number: 458699
Objectives: To evaluate fludarabine in patients with chronic lymphocytic leukaemia (CLL) not responding to standard treatment. Design setting: Fludarabine was administered for 5 consecutive days and repeated 4-weekly. Subjects: Seventeen patients at a single institution were treated. Outcome measures: Objective remission was seen in 11 patients. The median survival time was 356 days. Results and conclusions: Fludarabine is an effective treatment for patients with advanced CLL.